Back to discover
Disease
Wilms Tumor
Late-stage therapeutic developmentEmerging research
1
Publications
19
Clinical trials
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Children's Oncology Group's 2023 blueprint for research: Renal tumors.
Research2023-07-21Pediatric blood & cancer
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026Multi-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation
- Q3 2027Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
- Q4 2027A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Q3 2029A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
- Q1 2031Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Major developments
Major trial resultsHigh impact
Results posted2026-06-03
Major trial resultsHigh impact
Results posted2026-06-03
Clinical MilestonesView all 9Hide
Results posted
- 2026-06-11Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsResults posted
- 2026-06-03Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms TumorResults posted
- 2026-06-03Treatment for Very Low and Standard Risk Favorable Histology Wilms TumorResults posted
- 2026-06-03Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms TumorsResults posted
Results expected
- 2026-07-08A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorResults expected Q4 2027
- 2026-05-06A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid TumorsResults expected Q3 2029
- 2026-05-05Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)Results expected Q1 2031
- 2026-05-05Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)Results expected Q3 2027
- 2026-04-23Multi-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam IrradiationResults expected Q4 2026
+1 more in the activity timeline below
Activity timeline9
- 2026-07-08ClinicalA Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorResults expected Q4 2027
- 2026-06-11ClinicalPhase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsResults posted
- 2026-06-03ClinicalTreatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms TumorResults posted
- 2026-06-03ClinicalTreatment for Very Low and Standard Risk Favorable Histology Wilms TumorResults posted
- 2026-06-03ClinicalTreatment of Newly Diagnosed Higher Risk Favorable Histology Wilms TumorsResults posted
- 2026-05-06ClinicalA Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid TumorsResults expected Q3 2029
- 2026-05-05ClinicalRisk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)Results expected Q1 2031
- 2026-05-05ClinicalTreatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)Results expected Q3 2027
- 2026-04-23ClinicalMulti-Center Trial Sponsored by St. Jude Children's Research Hospital for the Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam IrradiationResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
5
5
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Recent publications
Major themes5
- Carcinoma, Renal Cell1
- Kidney Neoplasms1
- Rhabdoid Tumor1
- Sarcoma, Clear Cell1
- Wilms Tumor1
Leading journals1
- Pediatric blood & cancer1
Leading researchers8
- Aldrink JH1
- Cost NG1
- Evageliou N1
- Geller JI1
- Hong AL1
- Mullen EA1
- Renfro LA1
- Treece AL1
Affiliations (unnormalised)6
- Aflac Cancer and Blood Disorders Center1
- Children's Hospital of Philadelphia1
- Cincinnati Children's Hospital Medical Center1
- Cook Children's Medical Center1
- Dana-Farber/Boston Children's Blood Disorders and Cancer Center1
- Department of Pathology and Laboratory Medicine1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.